The Cortisol-Testosterone Seesaw at 47

The hormonal collapse pattern no one in your life has named yet

There is a story that men tell themselves about testosterone decline that goes roughly like this: it happens in your sixties, gradually, to other men, and you’ll deal with it when the time comes. I want to revise that story with some clinical precision, because the version I see in my practice looks quite different from the common narrative.

In a man who has been under significant chronic stress — which is to say, in many of the men reading this book — the hypothalamic-pituitary-gonadal axis has been under suppressive pressure from the hypothalamic-pituitary-adrenal axis since approximately his late thirties. The relationship between cortisol and testosterone is not metaphorical. It is physiological, bidirectional, and documented across decades of endocrine and neuroscience research. Testosterone suppresses CRH-stimulated cortisol production at the adrenal level; chronically elevated cortisol suppresses the HPG axis in return, primarily by reducing gonadotropin-releasing hormone pulsatility at the hypothalamus and by directly inhibiting Leydig cell testosterone synthesis in the testes. This is a bidirectional biological seesaw, and in the man who is forty-seven and running a company or a department or a household on perpetually elevated cortisol, the testosterone side of that seesaw has often been pressed down for years.

What he has been experiencing as “aging” and “slowing down” and “having less drive” is, in measurable biochemical terms, a compound endocrine event with cardiovascular consequences that extend well beyond quality of life. This chapter is about the mechanism, the clinical significance, what to measure, and what the evidence says — and doesn’t say — about what to do.

The HPA-HPG Axis: The Bidirectional Biology

To understand the cortisol-testosterone seesaw, you need to understand the two axes that run it and how they interact.

The hypothalamic-pituitary-adrenal axis — the HPA axis — is the primary stress response system. Under conditions of perceived threat or chronic load, the hypothalamus releases corticotropin-releasing hormone, or CRH. CRH signals the pituitary to release adrenocorticotropic hormone, or ACTH, which travels through the bloodstream to the adrenal glands and stimulates the production of cortisol. This is the system we have been discussing throughout this book: the allostatic load accumulator, the chronic stress amplifier, the mechanism through which years of professional and personal pressure become physiological wear.

The hypothalamic-pituitary-gonadal axis — the HPG axis — is the primary male reproductive hormone system. The hypothalamus releases gonadotropin-releasing hormone, or GnRH, in pulsatile bursts. GnRH signals the pituitary to release luteinizing hormone, or LH, which travels to the testes and stimulates Leydig cells to produce testosterone. Testosterone then provides negative feedback to the hypothalamus and pituitary, modulating its own production.

These two axes are not independent. A landmark 2002 review by Viau, published in the Journal of Neuroendocrinology, established the functional cross-talk between the HPA and HPG axes: testosterone inhibits HPA axis responsiveness, partly through direct action on hypothalamic CRH neurons. Glucocorticoids — primarily cortisol — inhibit the HPG axis through multiple mechanisms: direct reduction of GnRH pulsatility, direct inhibition of LH secretion from the pituitary, and direct Leydig cell suppression through glucocorticoid receptors expressed in testicular tissue.

The dual-hormone hypothesis formalized by Mehta and Josephs in 2010, published in Hormones and Behavior, gives this biology a behavioral dimension: testosterone predicts competitive, status-seeking, dominant behavior when cortisol is low — but when cortisol is simultaneously elevated, this association is blocked or reversed. The man under chronic cortisol load is not merely experiencing reduced testosterone effects; the cortisol is actively antagonizing what testosterone remains. In plain terms: the chronically stressed high-achieving man does not only feel less testosterone-driven. He is measurably producing less testosterone, and the testosterone he is producing is having less behavioral and physiological effect, because cortisol is sitting on the other end of the seesaw.

Normal Decline vs. Stress-Accelerated Decline

It is important to distinguish between the normal age-related decline in testosterone — which is real, gradual, and physiological — and the stress-accelerated decline that this chapter is primarily about, because these are different clinical situations with different implications.

A landmark longitudinal study by Harman and colleagues published in the Journal of Clinical Endocrinology & Metabolism in 2001, following 890 men over nine years in the Baltimore Longitudinal Study of Aging, found that total testosterone declines at approximately one percent per year after age thirty, with free testosterone declining slightly faster as sex hormone-binding globulin increases with age. This is the baseline physiological trajectory.

But in 2007, Travison and colleagues published a population-level analysis in the Journal of Clinical Endocrinology & Metabolism that revealed something far more alarming: comparing three cross-sectional cohorts from the Massachusetts Male Aging Study collected between 1987 and 2004, they found that testosterone levels in American men had been declining beyond what aging alone explained — at a rate of approximately 1.2 percent per year of observation period, independent of age. A man born in 1970 had approximately seventeen percent lower testosterone at any given age than a man born in 1940 at the same age. The authors controlled for obesity, smoking, and other confounders. The secular trend remained.

The proposed drivers of this population-level decline include increased prevalence of chronic stress, decreased sleep quality and duration, increased rates of obesity and metabolic syndrome, reduced physical activity, and possible environmental endocrine disruptors. Many of these are the same upstream drivers described throughout this book. The population data is consistent with the clinical observation that middle-aged men today are presenting with testosterone levels that previous generations did not see until a decade later.

For the man reading this who is forty-three or forty-seven and feels a qualitative shift in energy, drive, and physical capacity that seems disproportionate to his age: the population science says this may not be entirely in his head, and it may not be simply the inevitable trajectory of time. It may be the accumulated upstream load producing a measurable endocrine consequence.

The Symptom Constellation and Its Cardiovascular Significance

The symptoms associated with low testosterone in men are familiar to anyone who has treated this population: reduced libido, fatigue that is qualitatively different from ordinary tiredness, increased visceral fat particularly around the abdomen, reduced muscle mass and strength, mood changes that typically manifest as irritability, flattened affect, or reduced motivation rather than the classic depressive presentation, and cognitive fog — a subjective dulling of mental sharpness that men often describe as “not being as sharp as I used to be.”

These are quality-of-life symptoms, and they matter as quality-of-life symptoms. But I want to make a more pointed argument: each of these symptoms is also a cardiovascular risk factor in its own right, and the constellation of them together represents a cardiometabolic profile that belongs in a cardiovascular risk conversation, not merely in an endocrinology consultation.

Increased visceral fat — which testosterone deficiency promotes through reduced muscle mass and altered adipose metabolism — is a driver of insulin resistance, dyslipidemia, systemic inflammation, and the small, dense LDL phenotype that generates ApoB discordance. Reduced muscle mass reduces glucose uptake capacity and worsens insulin sensitivity. Mood changes and flattened affect are associated with reduced physical activity, poorer sleep, and higher levels of chronic sympathetic activation — each of which compounds the cardiovascular picture. The man with low testosterone is not simply experiencing a hormonal deficiency. He is running with a cardiometabolic phenotype that feeds back into the HPA dysregulation that suppressed his testosterone in the first place.

Low Testosterone as a Cardiovascular Risk Marker

The most clinically direct argument for including testosterone in a cardiovascular risk assessment is the prospective mortality data.

A prospective study by Laughlin and colleagues published in the Journal of Clinical Endocrinology & Metabolism in 2008 followed 794 men in the Rancho Bernardo Study and found that men in the lowest quartile of testosterone — below approximately 10.4 nmol/L, or 300 ng/dL — had significantly increased all-cause and cardiovascular mortality after adjusting for age, adiposity, physical activity, and established cardiovascular risk factors. The association was independent and substantial.

This finding has been replicated. A study by Khaw and colleagues published in Circulation in 2007 examined testosterone levels in 11,606 men from the European Prospective Investigation into Cancer and Nutrition cohort, and found that men in the lowest quartile of endogenous testosterone had significantly higher cardiovascular mortality over a seven-year follow-up period. The effect was independent of obesity, physical activity, blood pressure, and cholesterol.

A study by Shores and colleagues in male veterans, published in the Archives of Internal Medicine in 2006, found that low testosterone — defined as below the laboratory reference range — was associated with higher all-cause mortality over approximately 4.3 years of follow-up, with an effect size comparable to the known cardiovascular risk of hypertension.

The critical qualifier that belongs in this conversation — and which I will return to in detail — is that these associations are observational and bidirectional. Low testosterone may contribute to cardiovascular risk through the mechanisms I’ve described; cardiovascular disease and the metabolic syndrome that precede it may also suppress testosterone, meaning that low testosterone is partly a marker of systemic disease severity rather than simply a cause of it. This is not a reason to ignore low testosterone; it is a reason to investigate its upstream drivers rather than simply replacing the end-point hormone.

Metabolic Syndrome and the Hormonal Cascade

Visceral fat is not merely an inert repository of excess caloric storage. It is an endocrine organ — specifically, an organ that converts androgens to estrogens through aromatase activity. The adipose tissue of a man with a forty-two-inch waist and elevated triglycerides is producing measurable amounts of estradiol, which drives its own feedback suppression of hypothalamic GnRH production. The SHBG — sex hormone-binding globulin, the protein that carries testosterone in the blood and determines how much is bioavailable — is produced by the liver and is suppressed by insulin resistance and elevated by estrogen, creating a hormonal environment in the metabolically dysregulated man that reduces both total testosterone and the free fraction available to tissues.

This is the compound hormonal dysregulation of the metabolic man, and it creates a clinical situation that is worse than the sum of its parts. Chronic stress suppresses testosterone through the HPA-HPG axis. The resulting visceral fat produces estrogen and suppresses SHBG. Insulin resistance further disrupts the hormonal environment. The sleep disruption and OSA discussed in the previous chapter suppress testosterone independently, through the disruption of the slow-wave and REM architecture during which testosterone synthesis predominantly occurs. Each of these operates simultaneously, and in the man who carries all four inputs — chronic stress, visceral adiposity, metabolic dysregulation, and poor sleep — the testosterone level reflects the sum of these suppressors rather than the output of a normal HPG axis operating at its full capacity.

What to Measure: The Complete Hormonal Assessment

The standard approach to testosterone in American clinical practice — ordering a single “testosterone level” from a primary care visit without specifying the time of day, without measuring the free fraction, and without understanding what upstream factors might be suppressing it — is clinically inadequate. Here is what a complete hormonal assessment for a man with symptoms of testosterone deficiency should include, and why each element matters.

Total testosterone: The standard measurement, but with an important caveat: testosterone has a substantial diurnal variation, peaking in the morning and declining by as much as thirty-five percent by afternoon. The Endocrine Society and virtually all endocrine guidelines specify that testosterone should be measured in the morning, between 8 and 10 a.m., from a fasted or minimally fasted state, and should be confirmed on at least two separate occasions before a diagnosis of hypogonadism is made. A testosterone level drawn at 3 p.m. during a routine physical is close to clinically meaningless.

Free testosterone: Total testosterone includes testosterone bound to SHBG — which is biologically inactive — and free testosterone, which is available to androgen receptors in tissues. In men with high SHBG, total testosterone can be normal while free testosterone is significantly reduced. Measuring free testosterone, or calculating it from total testosterone and SHBG, provides a more clinically accurate picture of androgenic activity.

SHBG: Sex hormone-binding globulin levels tell you how much of the total testosterone is biologically available. High SHBG is associated with aging, elevated estrogen, and thyroid dysfunction. Low SHBG is associated with insulin resistance and obesity, and in this context may suggest that total testosterone overestimates bioavailability less than might be assumed.

LH (luteinizing hormone) and FSH: These pituitary hormones tell you where in the axis the problem lies. A man with low testosterone and appropriately elevated LH is experiencing primary hypogonadism — the testes are being stimulated adequately but are not responding. A man with low testosterone and low or normal LH — secondary hypogonadism — has a problem at the hypothalamic or pituitary level, which could include chronic stress suppression, pituitary adenoma, or other central causes. This distinction matters clinically because it determines the appropriate workup and management.

Estradiol: Elevated estradiol from aromatization in visceral fat can suppress HPG function and contribute to symptoms even when testosterone is borderline normal. Measuring estradiol completes the androgenic picture.

DHEA-S (dehydroepiandrosterone sulfate): DHEA-S is produced by the adrenal gland and is an androgen precursor. Its levels decline with age and under chronic HPA activation. Low DHEA-S in a man with the clinical picture described in this chapter supports the narrative of adrenal burden and upstream stress-mediated hormonal suppression.

Together, these six measurements take one blood draw (morning, ideally fasted), cost approximately sixty to one hundred fifty dollars depending on insurance and facility, and provide a complete hormonal snapshot that changes the clinical conversation from “your testosterone is low” to “here is why your testosterone is low, and here is where in the system the disruption is occurring.”

The Testosterone Replacement Therapy Conversation

I cannot write a chapter about testosterone without addressing testosterone replacement therapy, or TRT — because if you have low testosterone symptoms and you search for answers, TRT will be the dominant solution offered to you by large segments of the medical marketplace. I want to give you the cardiologist’s honest version of this conversation.

The evidence base for TRT is as follows, as of 2025.

The TRAVERSE trial, published in the New England Journal of Medicine in 2023 by Lincoff and colleagues, was the first adequately powered randomized controlled trial designed to assess the cardiovascular safety of TRT in hypogonadal men with established cardiovascular disease or high cardiovascular risk. 5,246 men received testosterone gel or placebo over a median of thirty-three months. The primary outcome — a composite of cardiovascular death, non-fatal MI, and non-fatal stroke — was non-inferior in the testosterone group compared to placebo, with hazard ratios that excluded substantial excess risk. This established that TRT does not appear to substantially increase short-term MACE in men with established CVD or high risk when monitored appropriately.

However, TRAVERSE also found higher rates of atrial fibrillation in the testosterone group (HR 1.35) and higher rates of pulmonary embolism (HR 1.92). These are real signals that require individualized risk discussion.

Separately, the T Trials cardiovascular substudy by Budoff and colleagues, published in JAMA in 2017, found that testosterone treatment significantly increased non-calcified coronary artery plaque volume at twelve months in older men with low testosterone — a surrogate marker signal that requires reconciliation with the TRAVERSE safety data and has not been fully resolved.

The honest cardiologist’s synthesis: TRT has been established as not dramatically increasing short-term MACE in appropriately selected, monitored patients, but it has not been established as providing cardiovascular benefit, and it carries specific safety signals that require individualized evaluation. In men whose low testosterone is driven primarily by upstream suppressors — chronic stress, visceral adiposity, sleep disruption, and metabolic dysfunction — addressing those upstream factors first, before considering TRT, is both clinically appropriate and consistent with the evidence. Many men see meaningful testosterone recovery when they lose visceral fat, improve sleep, reduce HPA burden, and introduce resistance training. The man who goes directly to TRT without addressing these upstream drivers is treating the reading on the gauge without addressing what is suppressing the engine.

The Endocrine Society’s clinical practice guidelines, most recently updated in 2018 and reaffirmed in 2023, recommend TRT only for men with confirmed hypogonadism — based on morning testosterone levels below the laboratory normal range on two separate occasions, plus one or more symptoms attributable to testosterone deficiency — and specify that the decision to treat should follow a discussion of the available evidence on benefits and risks. The Endocrine Society guidelines explicitly do not recommend TRT as a treatment for age-related testosterone decline in the absence of clinically defined hypogonadism.

This is a conversation to have with your physician or an endocrinologist, with your numbers on the table, not a decision to make based on direct-to-consumer testosterone marketing.

The Testosterone-Cardiovascular Risk Conversation in 2025

I want to be precise about the current state of the evidence, because the clinical landscape on testosterone and cardiovascular risk has shifted substantially in the past five years and the public conversation — in medical media, wellness podcasting, and direct-to-consumer health marketing — has not fully caught up with the nuance.

There are three distinct clinical questions here, and they are often conflated in ways that produce confusion.

Question One: Does low endogenous testosterone predict cardiovascular events? The observational answer is yes, robustly and consistently across multiple large cohort studies. But observational data cannot resolve causality: low testosterone may contribute to cardiovascular risk through metabolic mechanisms, or it may simply reflect the severity of the underlying metabolic disease that also drives cardiovascular risk, or both. The clinical implication of this ambiguity is not nihilism; it is that a low testosterone finding should prompt investigation of the upstream metabolic drivers rather than immediate hormonal replacement.

Question Two: Is testosterone replacement therapy safe from a cardiovascular standpoint? The best available evidence, from the TRAVERSE trial, says yes — with caveats. Non-inferiority for MACE was established in appropriately selected, monitored patients over approximately three years. But non-inferiority for MACE is not the same as absence of cardiovascular risk: the atrial fibrillation and pulmonary embolism signals from TRAVERSE are real and require individualized evaluation. A man with a pre-existing arrhythmia, thromboembolic history, or polycythemia risk — elevated red blood cell mass is a consistent TRT side effect requiring monitoring through hematocrit checks — has a different risk-benefit calculation than one without these features.

Question Three: Does testosterone replacement therapy improve cardiovascular outcomes? The honest answer, as of 2025, is no — not definitively established. TRAVERSE was designed to assess safety, not efficacy for cardiovascular outcomes. The T Trials substudy by Budoff showing increased non-calcified plaque volume with testosterone treatment in older men is a concerning signal that has not been resolved by TRAVERSE’s MACE data. The claim — made frequently in wellness media — that testosterone replacement is heart-protective is not consistent with the current evidence base, and I will not make it here.

What the evidence does support is this: testosterone is a cardiovascular hormone, its deficiency is associated with cardiovascular risk, and the man with confirmed clinical hypogonadism (not just low-normal levels) has legitimate grounds for a shared decision conversation about TRT with his physician, with the understanding that the decision should be based on symptom burden and confirmed biochemical deficiency, not on the aspiration to feel twenty-five again.

Understanding the “Normal” Range Problem

Before leaving the testosterone discussion, I want to address the single most common clinical frustration I hear from men who have had their testosterone measured: being told the result is “normal” while experiencing every symptom of insufficiency.

The laboratory reference range for total testosterone in American men is typically listed as 264 to 916 ng/dL. This range was derived by measuring testosterone in large populations of men and taking the middle ninety-five percent. It includes men who are healthy and metabolically fit. It also includes men who are sedentary, obese, chronically stressed, sleep-deprived, and metabolically dysregulated. The man at 310 ng/dL is in the “normal” range by laboratory standards. He is also at the same level one would expect in a metabolically compromised eighty-year-old man. He is forty-four.

This is not a fringe critique. The Endocrine Society’s clinical practice guidelines specify that the target for testosterone replacement in treated hypogonadal men should be the mid-normal range for healthy, young men — roughly 500 to 700 ng/dL — not the bottom of the reference range. The bottom of the range exists because the reference range was designed to be inclusive of a general population, not because men at the bottom third of that range are experiencing hormonal adequacy.

The clinical take is this: if you have symptoms consistent with testosterone deficiency — reduced libido, fatigue not explained by other causes, reduced muscle mass, mood changes — and your testosterone comes back at 310 or 340 ng/dL, you are not experiencing normal testosterone function. You are experiencing testosterone that falls within a statistical distribution that was never designed to define hormonal optimization. The appropriate clinical response is not “your testosterone is fine, come back in a year.” It is an investigation of the upstream drivers that may be suppressing your HPG axis and an honest conversation about whether the clinical picture warrants intervention.

Lifestyle Interventions with Evidence

For the man who wants to address his hormonal picture through means other than, or prior to, pharmacological intervention, the evidence base for lifestyle approaches is more substantial than is widely communicated. Let me be specific.

Resistance training is the most robustly evidence-supported lifestyle intervention for testosterone in middle-aged men. Multiple randomized studies have found that progressive resistance training — three or more sessions per week, with compound movements like deadlifts, squats, and rows at intensities of seventy to eighty-five percent of one-repetition maximum — increases total and free testosterone in men aged forty to sixty. The mechanism involves both acute testosterone surges post-exercise and chronic adaptations in HPG axis sensitivity. The effect size is typically moderate — approximately ten to fifteen percent increase in resting testosterone — but meaningful in a man who is starting from a suppressed baseline. Resistance training also independently reduces visceral fat, improves insulin sensitivity, and reduces the aromatase-driven estrogen conversion that further suppresses testosterone. It is the single most evidence-supported lifestyle modification for the hormonal picture described in this chapter.

Sleep: As established in Chapter 5, testosterone production is predominantly sleep-dependent. Addressing OSA, improving sleep duration, and protecting sleep architecture are direct interventions for the testosterone-suppression pathway. The Liu et al. 2022 review in Reviews in Endocrine and Metabolic Disorders quantified the sleep-testosterone relationship clearly: even partial sleep deprivation produces measurable testosterone suppression within days, and the effect is reversible with sleep restoration. For the man with untreated OSA and testosterone in the low-normal range, a sleep study and CPAP treatment is hormonal intervention, whether or not it is framed that way.

Visceral fat reduction improves testosterone both by reducing aromatase activity and by improving insulin sensitivity, which in turn reduces SHBG suppression. The clinical data supports a correlation of approximately fifty ng/dL increase in total testosterone per ten-kilogram reduction in body weight in obese men — a meaningful effect. The mechanism is upstream correction, not hormonal supplementation.

Stress reduction: The clinical evidence for stress reduction as a testosterone intervention is less robustly quantified than for exercise or sleep, but it is biologically coherent and supported by observational data on the HPA-HPG relationship. The man who reduces his chronic cortisol burden — through any combination of HPA-reducing interventions — removes a direct suppressor of the HPG axis. What this looks like in practice is not a prescription for meditation retreats; it is attention to the specific upstream drivers of HPA activation: workload, sleep, social connection, physical activity, and clinical treatment of anxiety or depression when present.

Clinical Pearl — If you read nothing else in this chapter: A prospective study by Laughlin and colleagues published in the Journal of Clinical Endocrinology & Metabolism in 2008 found that low serum testosterone — below the lowest quartile — was independently associated with significantly increased all-cause and cardiovascular mortality in older men after adjusting for age, adiposity, lifestyle factors, and cardiovascular risk. Testosterone is not merely a sex hormone or a quality-of-life hormone. It is a cardiovascular hormone, and its measurement — performed correctly, in the morning, with free testosterone and SHBG — belongs in any serious cardiovascular risk assessment for a man between thirty-five and sixty.

James, 47, runs a construction company with sixty employees. He has gained twenty pounds over the past four years, predominantly around his waist. His libido is low enough that he has made excuses to his wife three nights a week for the past eight months. He feels foggy in the afternoons and needs two cups of coffee to get through the post-lunch hours. He exercises occasionally. He sleeps six hours most nights. His previous physician ordered a testosterone level at his last physical — at 2 p.m., not fasted — which came back at 312 ng/dL. The physician told him this was “low normal” and suggested he try exercising more. James presented to my clinic after his wife’s repeated request. A morning testosterone level — fasted, 8:15 a.m. — came back at 278 ng/dL. His free testosterone was low. His LH was 3.2 IU/L — inappropriately low for a suppressed testosterone, indicating secondary hypogonadism. His cortisol was elevated. His SHBG was 19 nmol/L. His fasting insulin was 18 μIU/mL. His waist was 43 inches. His AHI from a subsequent sleep study was 19 events per hour. The clinical picture was not testosterone deficiency requiring TRT. It was a man with chronic HPA activation, insulin resistance, visceral adiposity, moderate OSA, and sleep deprivation whose HPG axis was being suppressed by every element of his metabolic and endocrine environment simultaneously. Six months later — after CPAP, structured resistance training three days per week, dietary modification that reduced his visceral fat by eight pounds, and consistent sleep of seven and a half hours — his morning testosterone is 488 ng/dL without a single injection, gel, or prescription androgen. His wife has stopped making excuses for him.

What to Do This Week

1. If you have not had a testosterone level measured in the past two years — or if your last measurement was not done in the morning, fasted, before 10 a.m. — ask your physician at your next visit to order total testosterone, free testosterone, SHBG, and LH. Specify the morning timing explicitly. This four-panel assessment takes one additional blood tube and gives a complete picture rather than a partial one.

2. Assess your weekly resistance training. “Walking” and “some exercise” are not resistance training. Progressive resistance training — weighted compound movements performed regularly against progressively increasing loads — is the lifestyle intervention with the strongest evidence for testosterone support. If you are not doing this currently, the first step is not a gym membership; it is a single conversation with your physician about whether there is any contraindication to initiating it.

3. Revisit the STOP-BANG score from Chapter 5. If you score three or above, the sleep study question and the testosterone question are part of the same clinical conversation. Sleep and testosterone are not separate issues. They are upstream and downstream of each other. If you have symptoms of low testosterone and have never been evaluated for OSA, bring both questions to your physician in the same visit. They are related.

Transition to Chapter 9

Your smartwatch knows you are not sleeping well. It may be showing you a declining HRV score, a shortened deep-sleep window, a recovery metric that trends slightly downward week over week. Chapter 9 is about what that number means, what it doesn’t mean, why wearable data has become, for a specific subset of men in this readership, a sophisticated way of feeling like they are managing their cardiovascular health without ever having the conversation that would actually require them to do something about it — and what I think about that, after twenty years of sitting across from men who had excellent numbers on their devices and difficult numbers on their echocardiograms.

End of Chapters 5–8

Source Reference Summary

The following primary sources are cited inline throughout Chapters 5–8. Full citation details are embedded in the text.

Chapter 5 — Sleep and OSA:

• Marin et al. (2005), The Lancet, PMID: 15781100 — Severe untreated OSA and cardiovascular mortality
• McEvoy et al. (2016), SAVE Trial, NEJM, PMID: 27571048 — CPAP and CVD events in established CVD
• Javaheri et al. (2024), JACC, PMC11666391 — OSA-cardiovascular mechanisms review
• Punjabi et al. (2009), PLOS Medicine, DOI: 10.1371/journal.pmed.1000132 — Sleep-disordered breathing and mortality
• Liu et al. (2022), Reviews in Endocrine and Metabolic Disorders, PMC9510302 — Sleep, testosterone, and cortisol
• Pruessner et al. (2003), JCEM — Cortisol awakening response and blood pressure
• Vyas et al. (2012), BMJ, PMID: 22835925 — Shift work and cardiovascular mortality meta-analysis
• JAMA Cardiology masked hypertension (2021) — Masked asleep hypertension prevalence

Chapter 6 — ApoB and Lp(a):

• Sniderman et al. (2022), JAHA, DOI: 10.1161/JAHA.122.025858 — ApoB physiological and clinical superiority
• Marston et al. (2022), JAMA Cardiology, PMID: 34935880 — ApoB vs. LDL-C in MESA
• Borén et al. (2020), European Heart Journal, DOI: 10.1093/eurheartj/ehz962 — LDL particles and ASCVD causality
• AHA (2024), ATVB, DOI: 10.1161/ATVBAHA.124.319483 — Lp(a) review
• ESC/EAS Dyslipidaemia Guidelines (2019), European Heart Journal, 41(1):111–188

Chapter 7 — CAC:

• Detrano et al. (2008), MESA, NEJM, DOI: 10.1056/NEJMoa072100 — CAC and coronary events
• Blaha et al. (2016), Atherosclerosis, PMC4764445 — 15-year CAC mortality
• Yeboah et al. (2014), JAMA, DOI: 10.1001/jama.2014.5979 — CAC reclassification vs. other markers
• Rao et al. (2025), PubMed PMID: 40893521 — CAC ≥400 and MACE risk
• Greenland et al. (2018), ACC/AHA Cholesterol Guidelines, JACC, DOI: 10.1016/j.jacc.2018.11.003
• Princeton IV Consensus (2024), Mayo Clinic Proceedings, DOI: 10.1016/j.mayocp.2024.06.002

Chapter 8 — Testosterone and HPA-HPG:

• Laughlin et al. (2008), JCEM, DOI: 10.1210/jc.2007-1792 — Low testosterone and mortality
• Harman et al. (2001), JCEM, DOI: 10.1210/jcem.86.2.7219 — Longitudinal testosterone decline
• Travison et al. (2007), JCEM, DOI: 10.1210/jc.2006-1375 — Population-level testosterone decline
• Viau (2002), Journal of Neuroendocrinology, DOI: 10.1046/j.1365-2826.2002.00798.x — HPA-HPG cross-talk
• Mehta & Josephs (2010), Hormones and Behavior, DOI: 10.1016/j.yhbeh.2010.08.020 — Dual-hormone hypothesis
• Khaw et al. (2007), Circulation, DOI: 10.1161/CIRCULATIONAHA.107.712786 — Endogenous testosterone and mortality
• Shores et al. (2006), Archives of Internal Medicine, DOI: 10.1001/archinte.166.15.1660 — Low testosterone and veteran mortality
• Liu et al. (2022), Reviews in Endocrine and Metabolic Disorders, PMC9510302 — Sleep-testosterone triad
• Lincoff et al. (2023), TRAVERSE, NEJM, PMID: 37326322 — TRT cardiovascular safety
• Budoff et al. (2017), T Trials, JAMA, DOI: 10.1001/jama.2016.21043 — TRT and coronary plaque

Document: sde_book_draft_part2_ch5-8.md